Loading stock data…
ASND
$220.93-8.45 (-3.68%)
Market ClosedLast close May 1
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ascendis Pharma A/S in the Healthcare sector is trading at $220.93. The stock is currently 12% below its 52-week high of $250.74, remaining 5.1% above its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why ASND maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$220.93
Potential Upside
5%
Whystock Fair Value$231.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$297.66+34.7%
Range$255.09 – $340.24
Fundamentals
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
140.05%
Volume
Today's trading volume
452,305
Recent News
Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Ascendis Pharma A/S (NASDAQ:ASND) ranks 9th on this list. The primary catalyst for hedge fund interest in Ascendis Pharma A/S (NASDAQ:ASND) stock over the past few weeks is the FDA approval of YUVIWEL for children with achondroplasia. Earlier this month, […]
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were higher late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were falling sharply late Tuesday
We Might See A Profit From Ascendis Pharma A/S (NASDAQ:ASND) Soon
We feel now is a pretty good time to analyse Ascendis Pharma A/S' ( NASDAQ:ASND ) business as it appears the company...
European Equities Traded in the US as ADRs Rise in Tuesday Trading
European equities traded in the US as American depositary receipts rose late Tuesday morning with th